Jazz Pharmaceuticals (JAZZ) Cash Flow Statement

Click line-items for a historical chart and %

Net income (loss)
Depreciation	8.17M
Amortization of intangible assets	75.83M
Loss on disposal of property and equipment	3K
Stock-based compensation expense	74.49M
Long-term debt, non-cash interest expense	16.42M
Loss on extinguishment of debt
Accounts receivable	-28.27M
Inventories	-14.12M
Prepaid expenses and other current assets	-8.51M
Other assets
Accounts payable	-4.29M
Accrued liabilities	-9.65M
Deferred revenue	-682K
Deferred rent
Liability under government settlement
Net cash provided by operating activities	409.84M
Purchases of property and equipment	-6.56M
Purchase of product rights	-150M
Decrease in restricted cash and investments
Net cash used in investing activities	-1.75B
Repayment of senior secured notes (including $6,816 paid to a related party)
Payments of debt extinguishment costs (including $484 paid to a related party)
Proceeds from offerings of common stock, net of issuance costs
Proceeds from term loan, net
Repayment of term loan	-19.28M
Proceeds from employee stock purchases, exercise of stock options and warrants
Net repayments under revolving credit facilities
Net cash used in financing activities	713.03M
Net increase (decrease) in cash and cash equivalents	-622.22M
Cash and cash equivalents, at beginning of period	988.79M
Cash and cash equivalents, at end of period	366.57M

Entities mentioned with JAZZ

View All Entities